The $ 4m contingent payment is dependent on 2 performance hurdles being met by MKM and patientrack for the 12 months to 30 June 2019.
50% on $11m revenue
50% on $2m EBITDA
Given first half results for the full alcidion business, $7.3 revenue, loss of $0.5m, I expect them to earn 50 % from the revenue target, but miss on the EBITDA target.
If they do meet the EBITDA target, it shows a much better result in the second half, great for holders.
Ann: Section 708A Cleansing Notice and Appendix 3B, page-9
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
